Kingdom Board Strengthened By The Appointment Of Industry Leader Dr. Jeanne Bolger

Kingdom Therapeutics has announced the appointment of experienced biopharmaceutical industry executive Dr Jeanne Bolger, to its Board.

Dr. Bolger brings a wealth of executive, business, and clinical development expertise as Kingdom Therapeutics builds upon positive preclinical data in our lead product, KT-20610, which targets the endocannabinoid system in the brain and the gut.

A 35-year veteran Pharma industry senior leader and registered medical doctor with over 20 years of experience in Licensing, M&A, Business Development, Alliance Management, and Venture Capital investment.

Dr. Bolger was Vice President, Venture Investments, at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) from 2013 to 2022. She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan.

Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Talking about the new appointment Liz Shanahan, CEO of Kingdom Therapeutics said:

“The addition of Jeanne to our board bolsters an already robust panel of industry experts, patient advocates, and business leaders supporting Kingdom Therapeutics. The insight and expertise that Jeanne will add as an advisor to our  board is invaluable, particularly as we progress from the pre-clinical trails phase towards our phase II study.”

Find out more about Kingdom Therapeutics’ Board of Directors here.